Company: PAII-WT
Filing Date: 2025-05-29
Form Type: DRS
Source: 0001213900-25-049013
Chunk: 6

Company: Pyrophyte Acquisition Corp. II
Filing Date: 2025-05-29
Form: DRS
Chunk 6
---
 to exercise redemption rights with respect to a large number of our shares and the amount of deferred underwriting compensation may not allow us to complete the most desirable business combination or optimize our capital structure, and may substantially dilute your investment in us” on page52, “ Risk Factors—We may issue additional Class A ordinary shares or preference shares to complete our initial business combination or under an employee incentive plan after completion of our initial business combination. We may also issue Class A ordinary shares upon the conversion of the Class B ordinary shares at a ratio greater than one -to -one at the time of our initial business combination as a result of the anti -dilution provisions contained therein. Any such issuances would dilute the interest of our shareholders and likely present other risks” on page68, “ Dilution” on page 115 and “ Proposed Busine ss—Ou r Sponsor” on page 134 for more information. In addition, our sponsor has committed to purchase an aggregate of 5,050,000 warrants, each exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.00 per warrant, or $5,050,000, in a private placement that will close simultaneously with the closing of this offering, which we refer to collectively as the “private placement warrants.” Each whole private placement warrant is exercisable subject to adjustment, terms and limitations as described herein. The private placement warrants will become exercisable 30 days after the completion of our initial business combination, as described in this prospectus. The private placement warrants are identical to the public warrants sold in this offering, subject to certain limited exceptions as described in this prospectus. Certain accredited investors (which may include certain of our directors, officers and advisors other than Sten Gustafson and Bernard Duroc -Danner), which we refer to as the “non -managingsponsor investors” throughout this prospectus, have expressed an interest to purchase, indirectly through the purchase of non -managingsponsor membership interests, an aggregate of [•] of the 5,050,000 total private placement warrants to be purchased and [•] of the 7,255,952 total founder shares held by our sponsor, assuming that the underwriters’ over -allotmentoption is exercised in full. As further described in “ Summary—Our Sponsor,” commencing on the date on which our securities are listed on the NYSE, we expect to make certain payments and reimbursements, or pay certain